Cost-effectiveness of Tdap vaccination of adults aged ≥65 years in the prevention of pertussis in the US: A dynamic model of disease transmission

PLoS ONE

Volumn 9, Issue 1, 2014, Pages

  McGarry, Lisa J ^a   Krishnarajah, Girishanthy ^b   Hill, Gregory ^a   Masseria, Cristina ^b   Skornicki, Michelle ^a   Pruttivarasin, Narin ^a   Arondekar, Bhakti ^b   Roiz, Julie ^b   Pelton, Stephen I ^c   Weinstein, Milton C ^a,d  

^a OPTUM   (United States)

^b GLAXOSMITHKLINE   (United States)

^c BOSTON UNIVERSITY   (United States)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIPHTHERIA PERTUSSIS TETANUS VACCINE;

ADOLESCENT; ADULT; AGED; ARTICLE; CHILD; COMPARTMENT MODEL; COST CONTROL; COST EFFECTIVENESS ANALYSIS; DISEASE SEVERITY; DISEASE TRANSMISSION; EARLY INTERVENTION; HUMAN; INFANT; INFECTION PREVENTION; PERTUSSIS; POPULATION RESEARCH; QUALITY ADJUSTED LIFE YEAR; SENSITIVITY ANALYSIS; STEADY STATE; UNITED STATES; VACCINATION;

ADULT; COST-BENEFIT ANALYSIS; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; MODELS, ECONOMIC; UNITED STATES; VACCINATION; WHOOPING COUGH;

EID: 84897522814     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0072723     Document Type: Article

References (51)

1. National Network for Immunization Information (2011) Pertussis (Whooping Cough). Available at http://www.immunizationinfo.org/vaccines/pertussis- whooping-cough. Accessed 21 Jul 2011.
2. Centers for Disease Control and Prevention (2006) Preventing Tetanus, Diphtheria, and Pertussis Among Adolescents: Use of Tetanus Toxoid, reduced Diphtheria Toxoid and Acellular Pertussis Vaccine: recommendations of the Advisory Committee on immunization Practices (ACIP). MMWR 55(RR-17):1-44.
3. Centers for Disease Control and Prevention (2011) Pertussis: Summary of Vaccine Recommendations. Available at http://www.cdc.gov/vaccines/vpdvac/ pertussis/recs-summary.htm. Accessed 21 Jul 2011.
4. Centers for Disease Control and Prevention (2012) National and State Vaccination Coverage Among Adolescents Aged 13-17 Years - United States, 2011. MMWR 61(34):671-677.
5. Centers for Disease Control and Prevention (2012) Adult Vaccination Coverage - United States. MMWR 61(04): 66-72.
6. Centers for Disease Control and Prevention (2012) Surveillance & Reporting.- Trends.US reported pertussis incidence 1990-2011. Available at http://www.cdc.gov/pertussis/images/incidence-graph-age.jpg Accessed 21 Jul 2012.
7. Centers for Disease Control and Prevention (2012) Pertussis Epidemic - Washington, 2012. MMWR 61(28):517-522.
8. California Department of Public Health (2011) Pertussis Report September 15, 2011. Available at: http://www.cdph.ca.gov/programs/immunize/Documents/ PertussisReport20119.pdf
9. Klein NP, Bartlett J, Rowhani-Rahbar A, Fireman B, Baxter R (2012) Waning protection after fifth dose of acellular pertussis vaccine in children. N Engl J Med 367:1012-1019.
10. Cortese MM, Baughman AL, Brown K, Srivastava P (2007) A "new age" in pertussis prevention new opportunities through adult vaccination. Am J Prev Med 32(3):177-185.
11. Roush SW, Murphy TV, and the Vaccine-Preventable Disease Table Working Group (2007) Historical comparisons of morbidity and mortality for vaccinepreventable diseases in the United States. JAMA 298(18):2155-2163. (Pubitemid 350106654)
12. Epidemiology and Prevention of Vaccine-Preventable Diseases (2012) The Pink Book: Course Textbook - 12th Edition Second Printing Available at http://www.cdc.gov/vaccines/pubs/pinkbook/pert.html
13. Cherry JD (2005) The epidemiology of pertussis: a comparison of the epidemiology of the disease pertussis with the epidemiology of Bordetella pertussis infection. Pediatrics 115:1422-1427.
14. deVries R, Kretzschmar M, Schellekens JF, Versteegh FG, Westra TA, et al. (2010) Cost-effectiveness of adolescent pertussis vaccination for the Netherlands: using an individual-based dynamic model. PLoS One 5(10):e13392.
15. Coudeville L, Van Rie A, Getsios D, Caro JJ, Crépey P, et al. (2009) Adult vaccination strategies for the control of pertussis in the United States: an economic evaluation including the dynamic population effects. PLoS One 16;4(7):e6284.
16. Lee GM, Murphy TV, Lett S, Cortese MM, Kretsinger K, et al. (2007) Cost effectiveness of pertussis vaccination in adults. Am J Prev Med 32(3):186-193.
17. Westra TA, de Vries R, Tamminga JJ, Sauboin CJ, Postma MJ (2010) Costeffectiveness analysis of various pertussis vaccination strategies primarily aimed at protecting infants in the Netherlands. Clin Ther 32(8):1479-95.
18. McGarry LJ, Krishnarajah G, Hill G, Masseria C, Skornicki M, et al. (2013) Cost-Effectiveness of Tdap vaccination in the US: a static model. PLoS One 3;8(9):e67260.
19. InfanrixH Prescribing Information (2010) GlaxoSmithKline. Available at http://us.gsk.com/products/assets/us-infanrix.pdf. Accessed 10 Mar 2011.
20. Schmitt HJ, von König CH, Neiss A, Bogaerts H, Bock HL, et al. (1996) Efficacy of acellular pertussis vaccine in early childhood after household exposure. JAMA 275(1):37-41. (Pubitemid 26004253)
21. GSK - data on file. Pertussis Universal Routine Protection from Little to Elderly (PURPLE) Model.
22. Beeler Asay GR (2011) Tdap vaccination to prevent pertussis in infants: a decision and cost-effectiveness analysis. National Center for Immunization and Respiratory Diseases Centers for Disease Control and Prevention http://www.cdc.gov/vaccines/recs/acip/downloads/mtg-slides-jun11/ 05-3-pertuss-tdap.pdf .Accessed 16 Aug 2011.
23. Wendelboe AM, Van Rie A, Salmaso S, Englund JA (2005) Duration of immunity against pertussis after natural infection or vaccination. Pediatr Infect Dis J 24(5 Suppl):S58-61. (Pubitemid 40676539)
24. Centers for Disease Control and Prevention (2010) National, State, and Local Area Vaccination Coverage among Children Aged 19-35 Months - United States, 2009. MMWR 59(36):1171-1177.
25. Centers for Disease Control and Prevention (2010) National, State, and Local Area Vaccination Coverage among Adolescents Aged 13-17 Years - United States, 2009. MMWR 59(32):1018-1023.
26. Centers for Disease Control and Prevention (2010) Tetanus and Pertussis Vaccination Coverage Among Adults Aged ≥18 Years - United States, 1999 and 2008. MMWR 59(40):1302-1306.
27. Centers for Disease Control and Prevention (2011) Summary of notifiable diseases-United States, 2009.58(53).p. 36
28. Acosta A (2012) Cost-effectiveness of Tdap substitution for Td in prevention of pertussis in adults 65 years and older. Presented to the Advisory Committee on Immunization Practices (ACIP), February 22, 2012. Atlanta, GA: US Department of Health and Human Services, CDC; 2012.
29. Zagheni E, Billari FC, Manfredi P, Melegaro A, Mossong J, et al. (2008) Using time-use data to parameterize models for the spread of close-contact infectious diseases. Am J Epidemiol 168(9):1082-1090.
30. Mossong J, Hens N, Jit M, Beutels P, Auranen K, et al. (2008) Social contacts and mixing patterns relevant to the spread of infectious diseases. PLoS Med 5(3):e74.
31. Lee GM, Lett S, Schauer S, LeBaron C, Murphy TV, et al. (2004) Massachusetts Pertussis Study Group. Societal costs and morbidity of pertussis in adolescents and adults. Clin Infect Dis 39(11):1572-1580. (Pubitemid 39578527)
32. Caro JJ, Getsios D, El-Hadi W, Payne K, O'Brien JA (2005) Pertussis immunization of adolescents in the United States: an economic evaluation. Pediatr Infect Dis J 24 (5 Suppl):S75-82. (Pubitemid 40676542)
33. Red Book (2010) Pharmacy's Fundamental Reference. Montvale, NJ: Thomson Reuters (Healthcare) Inc.
34. McDowell MA, Fryar CD, Ogden CL (2009) Anthropometric reference data for children and adults: United States, 1988-1994. Vital Health Stat 11 (249):1-68.
35. Physician's Fee and Coding Guide (2010) MAG Mutual Healthcare Solutions, 2009.
36. Lee LH, Pichichero ME (2000) Costs of illness due to Bordetella pertussis in families. Arch Fam Med 9(10):989-996. (Pubitemid 32014690)
37. O'Brien JA, Caro JJ (2005) Hospitalization for pertussis: profiles and case costs by age. BMC Infect Dis 11;5:57.
38. Molinari NA, Ortega-Sanchez IR, Messonnier ML, Thompson WW, Wortley PM, et al. (2007) The annual impact of seasonal influenza in the US: measuring disease burden and costs. Vaccine 25(27):5086-5096. (Pubitemid 46879994)
39. Bureau of Labor Statistics (2011) Consumer Price Index. Available at http://data.bls.gov/cgi-bin/srgate. Series ID: CUUR0000SAM. Accessed 21 Jul 2011.
40. Centers for Disease Control and Prevention (2010) Vaccine Price List. Available at http://www.cdc.gov/vaccines/programs/vfc/downloads/archived- pricelists/2010/12162010.htm#adult. Accessed 20 Dec 2010.
41. Bureau of Labor Statistics (2010) Current Population Survey 2010. http://www.bls.gov/cps/cpsaat3.pdf Accessed 16 May 2011.
42. Bureau of Labor Statistics (2011) Employment, Hours, and Earnings from the Current Employment Statistics survey (National).Available at http://www.census.gov/hhes/www/cpstables/032010/perinc/toc.htm. Accessed 16 May 2011.
43. Wells CD, Murrill WB, Arguedas MR (2004) Comparison of health-related quality of life preferences between physicians and cirrhotic patients: implications for cost-utility analyses in chronic liver disease. Dig Dis Sci 49(3):453-458. (Pubitemid 38453564)
44. Hanmer J, Lawrence WF, Anderson JP, Kaplan RM, Fryback DG (2006) Report of nationally representative values for the non institutionalized US adult population for 7 health-related quality-of-life scores. Med Decis Making 26(4):391-400. (Pubitemid 44050843)
45. Arias E (2010) 2006 US Life Tables. Natl Vital Stat Rep 58(21):1-40.
46. Gold MR, Siegel JE, Russell LB, Weinstein MC (eds) (1996) Cost-effectiveness in Health and Medicine. New York: Oxford University Press.
47. Clements KM, Chancellor J, Nichol K, DeLong K, Thompson D (2011) Costeffectiveness of a recommendation of universal mass vaccination for seasonal influenza in the United States. Value Health Sep-Oct;14(6):800-11.
48. Smith KJ, Wateska AR, Nowalk M, Raymund M, Nuorti J, et al. (2012) Cost-effectiveness of Adult Vaccination Strategies Using Pneumococcal Conjugate Vaccine Compared With Pneumococcal Polysaccharide Vaccine. JAMA;307(8):804-812.
49. Rothberg MB, Virapongse A, Smith KJ (2007) Cost-Effectiveness of a Vaccine to Prevent Herpes Zoster and Postherpetic Neuralgia in Older Adults. Clin Infect Dis 44 (10): 1280-1288. (Pubitemid 46717289)
50. Grenfell B (2011) Boosting understanding of pertussis outbreaks. Proc Natl Acad Sci U S A 108(18):7279-7280.
51. Centers for Disease Control and Prevention (2013) Noninfluenza Vaccination Coverage Among Adults - United States, 2011. MMWR 62(04);66-72.